AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company’s initial proprietary gene therapy candidate, AVXS-101, is in the pivotal phase of study for the treatment of spinal muscular atrophy (SMA) Type 1. The company also intends to expand the study of gene therapy into other types of SMA and two additional rare neurological monogenic disorders: Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene.

Contact AveXis
844.4.AVEXIS
Info@avexis.com
Visit Website